Next Article in Journal
Analysis of the Peritumoral Tissue Unveils Cellular Changes Associated with a High Risk of Recurrence
Previous Article in Journal
Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 15
Issue 13
10.3390/cancers15133449
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Analysis of Expression of Programmed Cell Death Ligand 1 (PD-L1) and BRAFV600E Mutation in Thyroid Cancer

by
Mizuki Sekino
1,
Manabu Iwadate
1,
Yukie Yamaya
1,
Yoshiko Matsumoto
1,
Satoshi Suzuki
1,
Hiroshi Mizunuma
1,
Keiichi Nakano
1,
Izumi Nakamura
1 and
Shinichi Suzuki
2,*
1
Department of Thyroid and Endocrinology, Fukushima Medical University, 1 Hikariga-oka, Fukushima City 960-1295, Japan
2
Department of Thyroid Treatment, Fukushima Medical University, 1 Hikariga-oka, Fukushima City 960-1295, Japan
*
Author to whom correspondence should be addressed.
Cancers 2023, 15(13), 3449; https://doi.org/10.3390/cancers15133449
Submission received: 25 May 2023 / Revised: 24 June 2023 / Accepted: 28 June 2023 / Published: 30 June 2023
Browse Figures
Review Reports Versions Notes

Abstract

:

Simple Summary

Immune checkpoint inhibitors are expected to be used in clinical practice to treat thyroid cancer. Programmed cell death ligand 1 (PD-L1) is the ligand expressed on the surface of tumor cells. Recent studies have reported that PD-L1 overexpression can impede T cell activation and result in tumor growth. In thyroid cancer, it has been suggested that PD-L1 overexpression is associated with some clinicopathological factors and prognosis. However, the characteristics of the tumor microenvironment of thyroid cancer or expression of PD-L1 have not yet been clarified; the effectiveness of anti-PD-L1 antibody to thyroid cancer is unclear. We found that PD-L1 expression is associated with BRAFV600E mutation, CD8+ expression and low T cell activation, suggesting a mechanism of tumor evasion from the immune surveillance system in thyroid cancer. This new finding suggests that immune checkpoint inhibitors can be also expected to be effective in thyroid cancer.

Abstract

In thyroid cancer, it has been suggested that PD-L1 overexpression is associated with some clinicopathological factors and prognosis. The aim of this study is to characterize the expression of PD-L1, the presence of the BRAFV600E mutation, as well as cellular and humoral immunity in thyroid cancer, and to investigate the factors that predict the effectiveness of anti-PD-L1 antibody therapy. Blood samples were collected from 33 patients who were newly diagnosed with thyroid cancer after surgery or biopsy. PD-L1 expression, BRAFV600E mutation, and CD8+ expression were examined by immunohistological staining using clinical thyroid cancer specimens. With a PD-L1 staining cut-off value of 1%, 13 (39.4%) patients were classified as PD-L1 positive. Stimulation Index (SI) is an indicator of T cell activation. PD-L1 expression was significantly correlated with low SI level (p = 0.046). Moreover, BRAFV600E mutation was detected in 24 of the 33 (72.7%) patients, and was significantly associated with PD-L1 expression (p = 0.047). In addition, enhanced CD8+ expression was significantly associated with PD-L1 expression (p = 0.003). Multivariate analyses confirmed that high CRP levels (p = 0.039) were independently and significantly associated with poor progression-free survival. These findings suggest that elevated PD-L1 status can be a prognostic indicator for survival in patients with thyroid cancer when comprehensively assessed using the expression of CD8+, the presence of BRAFV600E mutation and the patient’s immune status.

1. Introduction

Differentiated thyroid carcinomas (DTCs) include papillary thyroid carcinomas (PTCs) and follicular thyroid carcinomas (FTCs), and account for about 95% or more of thyroid carcinomas. The majority of DTCs have a good prognosis after treatment, but some DTCs have a poor prognosis, with repeated recurrence and metastasis. On the other hand, anaplastic thyroid cancer (ATC), one of the most lethal human solid cancers, has a median survival from diagnosis of about 6 months, and a one-year survival rate of less than 30%. ATC has been reported to be associated with the immune system and inflammatory conditions [1]. Blood tests often show leukocytosis, increased red sedimentation, and elevated c-reactive protein (CRP) levels. Recently, CRP and neutrophil–lymphocyte ratio (NLR) have been reported to be associated with cancer grade and poorer prognosis in not only ATC, but also DTC [2,3].
In addition, immune checkpoint inhibitors are also expected to be used in clinical practice to treat thyroid cancer. A phase Ib KEYNOTE-028 trial conducted to evaluate the safety and efficacy of pembrolizumab, an anti-PD-L1 antibody, evaluated patients with advanced differentiated thyroid cancer expressing programmed cell death ligand 1 (PD-L1) [4]. Several studies have shown the usefulness of PD-L1 expression in tumor cells [5,6], the amount of gene mutations in tumor [7], and lymphocytes that migrate to the cancer microenvironment [8] as biomarkers for selecting patients who are sensitive to cancer immunotherapy. However, biomarkers that can determine in advance the sensitivity or insensitivity of immune checkpoint inhibitors to thyroid cancer are lacking.
CD8 is a cell surface marker expressed on T cells. CD8+ T cells, which express CD8 co-receptor on their surface, are also known as cytotoxic T cells. CD8+ T cells recognize specific antigens presented by the MHC class I molecules on antigen-presenting cells, and upon activation, they target and kill infected cells or tumor cells. On the other hand, PDL1 is a protein that normally appears on the surface of antigen-presenting cells. The ligand for PDL1, PD1, is expressed on the surface of T cells. When PDL1 binds to PD1, T cell production of cytokines is reduced, and a signal is transmitted that suppresses T cell activity. PDL1 is also strongly expressed in tumor cells. When this PDL1 binds to PD1 on the surface of activated cytotoxic T cells, T cell activity is suppressed. Inactivated T cells then remain in the tumor microenvironment without migrating. Indeed, PD-L1 expression levels have been shown to be correlated with T cell infiltration [9], and such PD1/PDL1-mediated mechanisms represent tumor cell resistance to tumor immunity [10].
In recent years, it has been found that PDL1 is overexpressed in cancers such as non-small cell lung cancer (NSCLC), malignant melanoma, and renal cell carcinoma. Overexpression of PDL1 has been reported to be associated with resistance to anti-cancer therapy and poor prognosis [11,12,13]. Inhibitors that block immune checkpoints have been developed with the aim of weakening such resistance to tumor immunity and maintaining the body’s natural immune response to tumors. PD-L1 overexpression is found in approximately 46.4% of patients with thyroid cancer, and has been suggested to be a predictor of poor prognosis and recurrence, like in other cancers [14,15]. However, there are few studies on the prognostic significance of PD-L1 expression in thyroid cancer [16,17,18,19,20,21], and said significance remains controversial because of differences of the antibodies, scoring methods, and targeted histological types among said studies. The functions of cytotoxic T cells and helper T cells are regulated by many checkpoint molecules other than PD-L1, and the tumor microenvironment differs depending on the carcinoma. However, the characteristics of the tumor microenvironment of thyroid cancer and its relationship with PD-L1 have not been clarified. Therefore, it is unclear whether anti-PD-L1 antibody has the same therapeutic effect as malignant melanoma and non-small cell lung cancer, because there may be an immune escape mechanism unique to thyroid cancer.
Surgery is the first choice of thyroid cancer, while in high-risk cases, postoperative adjuvant therapies such as radioactive iodine therapy and thyroid hormone therapy are also employed. In recent years, there have been advancements in the development of targeted therapies for difficult-to-cure thyroid cancers, including radioactive iodine-refractory thyroid cancer, as a novel treatment approach [22]. The status of genetic mutations in thyroid cancer has become clearer, and it has been reported that certain genetic mutations influence the progression of thyroid cancer [23]. BRAFV600E mutation, RAS mutation, RET/PTC gene rearrangement, and TERT and p53 mutations are closely related to the characteristics and malignancy of thyroid cancer [24]. Some studies have reported that the BRAFV600E mutation is associated with indoleamine 2, 3-dioxygenase (IDO), human leukocyte antigen-G (HLA-G), PD-L1 expression, and a low CD8+ effector T cell to FoxP3+ suppressor T cell ratio [20,25,26]. Thyroid cancer encompasses a wide range of tumor types, with not only genetic mutations but also diverse molecular, histological, and clinical characteristics. Even patients with the same thyroid cancer type can select effective treatments depending on the type of genetic mutation and molecular characteristics. Therefore, to make risk-adapted and personalized treatments more available than ever before, it is necessary to identify as many powerful biomarkers as possible.
The aim of this study is to characterize the expression of PD-L1, the presence of the BRAFV600E mutation, and cellular and humoral immunity in thyroid cancer. Furthermore, the aim is to investigate whether specific factors can serve as indicators to enable the selection of anti-PD-L1 antibody therapy in thyroid cancer.

2. Materials and Methods

2.1. Patients

We used the data of blood samples and archival samples from all 33 patients with thyroid cancer who were newly diagnosed as having thyroid cancer and had undergone surgery or biopsy at Fukushima Medical University between January 2011 and January 2013 [27,28]. The age of patients at the time of surgery or biopsy was 57.6 ± 13.9 years (median 58 years, range 24–90). Thirty-three patients had histologically confirmed thyroid cancer, including twenty-four patients with PTC, five with ATC, two with medullary thyroid cancer (MTC) and two with FTC. All five patients with ATC exhibited undifferentiated transformation of PTC. We assessed the histological subtypes/variants of PTC using the 7th edition of the Japanese General Rules for the Description of Thyroid Cancer, which is based on the seventh classification of the Union for International Cancer Control (UICC). Of the 33 patients, 10 had stage I disease, 1 had stage II, 4 had stage III, and 18 had stage IV. For the four patients who did not undergo surgery, we determined their pT, pN, and stagings based on results from biopsy and ultrasonography.
This study was approved by the ethical committee of Fukushima Medical University (approval no. 29195), which is guided by local policy, national law, and the World Medical Association Declaration of Helsinki.

2.2. Immunohistochemistry

Four μm sections of formalin-fixed paraffin-embedded tissues of thyroid cancer were stained with Hematoxylin and Eosin stain, and underwent immunohistochemistry (IHC) analysis. IHC was carried out using the following primary antibodies: an anti PD-L1 (clone E1L3N; 1/200; Cell Signaling Technology, Inc., (CST), Danvers, MA, USA), anti BRAFV600E (clone VE1; 1/500; Spring Bioscience, Pleasanton, CA, USA), and anti CD8 (clone 4B11; ready to use; Leica BIOSYSTEMS Ltd., Newcastle, UK). We conducted IHC using a Bond Polymer Refine Detection kit (Leica Biosystems Ltd., Newcastle, UK) on an automated staining platform (BOND-III, Leica Biosystems Ltd., Newcastle, UK), following the manufacturer’s instructions [29].

2.3. Scoring of Immune Markers

PD-L1 and CD8 were analyzed using image analysis software Patholoscope at 400 magnification (Figure 1 and Figure 2). Since there are no established means to determine the PD-L1 expression rate or a cutoff value for positive expression using the PD-L1 antibody clone E1L3N, in this study, the rate of PD-L1 expression was determined by calculating the Tumor Proportion Score (TPS) based on a previous study [30]. First, the expression of PD-L1 was determined by membranous staining of tumor cells. Then, the rate of PD-L1 expression was determined using the Tumor Proportion Score (TPS), which is the proportion of tumor cells expressing PD-L1 among the total number of tumor cells. It was calculated as the number of tumor cells expressing PD-L1 divided by the total number of tumor cells, multiplied by 100%. A high value indicates strong expression of PD-L1, while a low value indicates weak or no expression of PD-L1. Moreover, based on the phase Ib KEYNOTE-028 trial, the cut-off value was determined to be 1% [4]. Patients were categorized into one of two groups according to a PD-L1 cut-off level of 1%; hence, <1% was designated as PD-L1-negative and ≥1% was considered PD-L1-positive. We determined CD8-positive if the entire cytoplasm was stained. Three non-overlapping fields on the HE-stained slides were selected, and the number of positive lymphocytes in all three fields was averaged [31,32]. The median value was used to separate the patient cohort into two groups; those with negative CD8 expression and those with positive CD8 expression.

2.4. Flow Cytometry

We analyzed peripheral blood mononuclear cells (PBMC) using flow cytometry to identify MDSCs, which were defined as CD11b + CD14 − CD33+ cells. Blood samples were labeled with fluorescein isothiocyanate (FITC), phycoerythrin (PE), and phycoerythrin-cyanin 5.1 (PC5), using antibodies directed against CD14 (Abcam, Cambridge, UK), CD11b (Beckman Coulter, Marseille, France), and CD33 (Beckman Coulter), respectively. The antibodies were diluted in phosphate-buffered saline (PBS) to 10 and 50 µg/mL, and cells were incubated with the antibodies at 4 °C for 20 min, then washed with PBS. Data acquisition and analysis were performed using a FACSAria II flow cytometer (BD Biosciences, Mountain View, CA, USA) and analyzed using FlowJo software (TreeStar Inc., Ashland, OR, USA) [27].

2.5. Cytokine Production by PBMCs

Around 106 PBMCs were cultured in 1 mL of RPMI-1640 medium with 10% heat-inactivated fetal calf serum (Gibco BRL, St. Louis, MO, USA) and 100 µg/mL phytohemagglutinin (PHA; Sigma, Rockville, MD, USA) at 5% CO2 and 37 °C for 24 h. Afterwards, the supernatants were collected and frozen at −80 °C until further use. To measure the concentrations of vascular endothelial growth factor (VEGF), interleukin (IL)-10, IL-12, IL-17, and IFN-γ, enzyme-linked immunosorbent assay (ELISA) kits from R&D Systems (Minneapolis, MN, USA) were utilized. Each sample was only used once after being thawed [27].

2.6. Lymphocyte Proliferation Assay

To assess lymphocyte proliferation, PBMCs were suspended in RPMI-1640 medium (Wako Pure Chemical Industries, Osaka, Japan) with 10% fetal calf serum (Sigma-Aldrich, St. Louis, MO, USA). The PBMC culture wells were then incubated with 10 µg/mL PHA at 37 °C in a 5% CO2 atmosphere for 80 h to induce PHA mitogenesis. During the last 8 h of incubation, 3H-thymidine (Japan Radioisotope Association, Tokyo, Japan) was added to the wells. The harvested cells were analyzed for 3H-thymidine incorporation using a liquid scintillation counter (PerkinElmer Inc., Waltham, MA, USA), and the results were expressed as counts per minute (CPM). To obtain the stimulation index (SI) for PHA-induced lymphocyte blastogenesis, the total CPM was divided by the control CPM. PBMCs that were not exposed to PHA were used as controls [27].

2.7. Markers of Inflammation and Thyroid Status

CRP, WBC, neutrophil lymphocyte rate (NLR), and lymphocyte to monocyte ratio (LMR) were used as indicators of inflammation. Thyroid status was evaluated with thyroid hormone (FT4, FT3, ATG, ATPO, HTG).

2.8. Statistical Analysis

The data presented in this study are reported as the mean values along with their corresponding standard deviations. The statistical significance of differences between groups was evaluated using Student’s t-test, and p < 0.05 was considered to indicate statistical significance. For cases where insufficient blood samples were collected from patients, certain measurements were not feasible. Fisher’s exact test, chi-square test, or Mann–Whitney U test was used as appropriate for statistical analysis. For patients who were alive and had not experienced relapse, the date of their last follow-up visit was used as the censoring date. Progression-free survival (PFS) was defined as the time interval between the date of surgery or biopsy and the date of disease progression, metastases, or death, and was calculated using the Kaplan–Meier method. The significance of differences in PFS was assessed using the log-rank test. Additionally, a Cox proportional hazard model was utilized for multivariate regression analysis. All statistical analyses were conducted using SPSS Statistics for Windows v26.0 (SPSS, Inc., Chicago, IL, USA).

3. Results

3.1. Correlation between PD-L1 Expression in Cancer Tissues and Clinicopathologic Factors

Characteristics of all patients (n = 33) are shown in Table 1. With a PD-L1 staining cut-off value of 1%, 20 (60.6%) patients were classified as negative (<1%), and the remaining 13 (39.4%) patients were classified as positive (≥1%). Stimulation Index (SI) is an indicator of T cell activation, and PD-L1-positive was positively associated with low SI levels (p = 0.046). Although no significant difference was observed, in the PD-L1-positive patients, the production of VEGF and IL-10 and MDSC that were immunosuppressive molecules were higher, and IL-12, IL-17, and INF-γ were lower, compared to the PD-L1-negative patients. The expression of PD-L1 was not related with tumor size, invasion, pTNM factors and UICC stagings, or any pathological features (p > 0.05) (Table 1).

3.2. Correlation between PD-L1 Expression and BRAFV600E Mutation

In this study, 24 (72.7%) patients were found to be positive for the BRAFV600E mutation, and nine (27.3%) were found to be positive for BRAF wild type. In the patients with BRAFV600E mutation, 22 had PTC and two had ATC, and none were mutated with FTC or MTC (p = 0.001). The BRAFV600E mutation was significantly associated with increasing expression of PD-L1. Twelve (50%) of twenty-four patients with BRAFV600E mutation were PD-L1 positive, compared to one (11.1%) of nine patients with BRAF wild type (p = 0.047) (Table 1).

3.3. Correlation between PD-L1 Expression and CD8+ Expression

When the median value of the number of positive T cells with CD8+ was classified as a cut-off, 16 (48.5%) patients out of the total 33 were negative and 17 (51.5%) patients were positive. CD8+ expression was significantly correlated with increased PD-L1 expression. Of the 17 patients with CD8+-positive, 11 (64.7%) were PD-L1 positive, compared to six (35.3%) CD8+ negative patients (p = 0.003) (Table 1).

3.4. Correlation between PD-L1 Expression in Thyroid Cancer and Patient Survival

The correlation between PFS and characteristics was examined using Cox proportional hazard model. The median follow-up period for cases was 55 months (range 0–92), during which 15 patients (45.5%) experienced tumor persistence, recurrence, or death. In the univariate analysis, several factors were independent predictors for poor PFS, including high CRP (HR = 5.08 [CI 1.26–64.76], p = 0.002), high WBC (HR = 30.93 [CI 2.81–340.82], p = 0.005), high VEGF (HR = 9.02 [CI 1.559–6.383], p = 0.029), primary tumor size ≥20 mm (HR = 7.79 [CI 1.74–34.78], p = 0.007), ATC (HR = 4.97 [CI 1.53–16.18], p = 0.008), extrathyroidal extension (HR = 9.3 [CI 2.28–37.9], p = 0.002), and distant metastasis (HR = 5.73 [CI 1.98–16.58], p = 0.001) (Table 2). On the other hand, patients with BRAFV600E mutation had a significantly favorable PFS (HR = 0.27 [CI 0.10–0.76], p = 0.013). There were no significant differences between elevated PD-L1 expression and PFS (HR = 1.04 [CI 0.37–2.91], p = 0.947) (Table 2).
In the multivariate analysis, all significant factors identified in the univariate analysis, including PD-L1 expression, were included. The results showed that BRAF wild type (p = 0.022) and high CRP (p = 0.039) were independent predictors for poor PFS (Table 3).
The Kaplan–Meier curve of BRAFV600E mutation showed a significant association with favorable PFS (p = 0.007), while the curve of PD-L1 expression and CD8+ expression showed no significant differences. However, these results suggested a potential trend towards poorer prognosis in CD8+ negative patients (Figure 3). Furthermore, we separated the 33 patients into four groups based on PD-L1 and CD8 expression (positive or negative) and BRAFV600E mutation or wild type, and subjected to sub-analyses. It was suggested that patients who were PD-L1-positive/CD8+-negative may have a tendency towards poor prognosis (Supplementary Figure S1, Supplementary Materials).

4. Discussion

We conducted IHC for PD-L1 expression in tumor cells and CD8+ infiltration within the tumor to investigate tumor immune status, and investigated the presence of BRAFV600E mutation which was the most representative genetic mutation among thyroid cancer, using surgical specimens from initial surgeries of 33 patients with thyroid cancer in our department. Blood samples were also collected from all 33 patients to measure immune suppressive cytokines, immune suppressive cells, markers of inflammation, and thyroid hormone levels. Furthermore, we evaluated the correlation between these factors and PD-L1 expression to investigate whether specific factors can serve as indicators to enable the selection of anti-PD-L1 antibody therapy in thyroid cancer. In our current study, 39.4% of the subjects were PDL1-positive.
In this study, there was no correlation between PD-L1 expression and clinicopathological factors such as tumor size, pTNM classification, or late-stage, which are known to be prognostic, and risk factors for recurrence of thyroid cancer as reported by Ahn S, et al. [25]. However, there is still a possibility of variation in the relationship between PD-L1 expression and telomerase reverse transcriptase (TERT) promoter mutation and RET/PTC, which were not tested in this study. Furthermore, the sample size in our study was limited. As each thyroid cancer has distinct clinical characteristics, it is necessary to increase the sample size and analyze the relationship between clinical–pathological variables and PD-L1 expression for each thyroid cancer subtype. Moreover, PD-L1 expression was not associated with prognosis. Previous studies have shown inconsistent findings regarding the association between PD-L1 expression and prognosis [1,14,16,25]. One reason for the discrepancies is the variability in the cutoff values used to classify PD-L1 expression as high or low. The optimal cutoff value for PD-L1 expression has not yet been validated for thyroid cancer [4]. The cutoff values currently used include 0%, 1%, 5%, 10%, 25%, or 30% and higher. In this study, we defined the cutoff value as 1% based on previous research [30]. Additionally, differences in the antibodies, experimental protocols, and scoring methods used to establish these cutoff values may also contribute to the discordance in results. We have been using the PD-L1 antibody clone E1L3N, having assessed its staining pattern for some time [33]. Because it is positioned in the Laboratory Developed Test (LDT), the criteria for stainability and the cutoff value have not been determined. Comparing the stainability of clone E1L3N with clone 28–8 and clone SP142, it was reported that they showed high degree of coincidence (Kappa coefficient = 0.69) [29]. Therefore, we trust that there was no problem in using clone E1L3N in this study. In order to apply clone E1L3N clinically, it is necessary to manage the precision of immunohistochemistry and standardize the scoring.
The present study also showed that patients who were PD-L1-positive had significantly higher levels of CD8+-positive expression. CD8+ T cells have been identified as significant factors for antitumor immunity. In fact, IHC images appear to show co-localization of PD-L1 staining and CD8 staining. In tumors rich in T cells, it has been shown that T cell infiltration into the tumor is activated and INF-γ is increased by the recognition of cancer cells [9]. Thus, we showed that, also in thyroid cancer, the expression of PD-L1 is upregulated to suppress the immune system from attacking cancer cells when T cells increase in the tumor microenvironment. Chronic exposure to antigens and immunosuppressive cells such as MDSCs can cause T cell dysfunction. The survival analysis in this study suggested that the PDL1-positive/CD8-negative group had a poor prognosis, indicating that the tumor immune response was suppressed. In such cases, immune checkpoint inhibitors can be expected to reactivate the immune response.
Stimulation Index (SI) is an indicator of T cell activation, and PD-L1-positivity was positively associated with low SI levels (p = 0.046). In the multivariate analysis, the results revealed that high CRP (p = 0.039) was an independent and significant predictive factor for poor PFS. CRP has been reported to be associated with cancer grade and poorer prognosis in not only ATC but also DTC [2,3]. Persistent inflammation and repeated exposure to tumor antigens in the tumor microenvironment gradually increase PD-1 activity and exhaust T cells. Due to the low activity level of T cells, there may be a possibility that the immune response against tumors is insufficient. Immunotherapy, such as immune checkpoint inhibitors, antibody therapy, and immunomodulatory therapy, can be effective in patients with low T cell activation levels by promoting T cell activation and inducing an appropriate immune response against tumors.
Moreover, a higher frequency of CD8+ T cells was found to be associated significantly with favorable survival in multiple tumors, including differentiated thyroid cancer [26,34,35]. This study also showed that CD8+ expression was significantly associated with prognosis. Further analysis revealed that the group with PD-L1-positive/CD8+-negative tended to have poorer prognosis. Combining the evaluation of CD8+ expression and PD-L1 expression may serve as a predictive biomarker for prognosis [17,18], and more research is needed.
The BRAFV600E mutation was significantly associated with increasing expression of PD-L1. It is suggested that the BRAFV600E mutation in thyroid cancer promotes immunosuppression and contributes to cancer immune evasion. On the other hand, it has been reported that there is no difference in prognosis between BRAFV600E mutation and BRAF wild type in Japan [36]. However, contrary to these findings, the present study showed that BRAFV600E mutation was independent and a significant predictive factor of favorable PFS. For one reason, the BRAF wild-type population in this study could include patients with aggressive fusion genes, such as RET/PTC and NTRK. Furthermore, it was possible that the difference in concept of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) between Japan and Western countries was reflected [37]. The major genetic mutation in NIFTP is the RAS mutation (29.6–59%) [38]. Therefore, it was suggested that the prognosis of BRAF wild type including NIFTP might be better than that of BRAFV600E mutation in Western countries. The relationship between BRAFV600E mutation and prognosis requires further investigation, and analysis is ongoing.
Our study had certain limitations, including its retrospective nature, relatively short median follow-up, and small sample size. The sample size was small, because the subjects of this study were further selected from those who participated in the previous study [27]. Prospective studies with larger sample sizes are needed to evaluate the correlation between PD-L1 expression, clinical response, and survival, and to establish the predictive value of PD-L1 expression, CD8+ TILs, and BRAFV600E mutation in thyroid cancer. Moreover, PD-L1 expression was analyzed at one selected hotspot rather than the entire tumor section, so it was considered that the heterogeneity in the tumor was not completely covered. Tumor genotype is associated with a particular subtype of thyroid cancer [39]. One of the reasons is that the amount of cancer-associated transcription factors varies from cell to cell. Norman G et al. revealed that the expression patterns of the transcription factors SP1 and TCF7L2, which were involved in gene expression, differed depending on types of FTC invasion. Moreover, in IHC, the factors tended to enhance expression along the tumor infiltration front relative to the central tumor [40]. Therefore, it may not be possible to make a precise diagnosis or predict prognosis by analyzing only one part of the heterogeneous tumor tissue, and we need to consider the method for individually analyzing cells composing tumors.
While there are many challenges ahead, it is a novel finding that comprehensive evaluation of factors such as PD-L1 expression, CD8 expression, BRAFV600E mutation, and the patient’s immune status can serve as prognostic indicators. It suggested the presence of mechanisms in which the immunological composition of the tumor microenvironment and inflammatory conditions influence the progression of thyroid cancer through PD-L1. Furthermore, by combining the evaluation of PD-L1 expression, CD8 expression, and BRAFV600E gene mutation status, it is possible to achieve more individualized patient risk classification. Additionally, the study presented results of PD-L1 expression in not only papillary thyroid carcinoma but also undifferentiated carcinoma, follicular carcinoma, and medullary carcinoma. In follicular carcinoma and medullary carcinoma, all patients showed negative PD-L1 expression. Although the sample size was small and no significant differences were observed, these data provide valuable insights as there are no prior studies reporting data on PD-L1 expression in thyroid cancers other than papillary and undifferentiated carcinoma.
As a prospect for defining risk classes of patients with thyroid cancer, we expect the development of predictive models that combine clinical, pathological, and genetic data. One useful way to make this feasible would be liquid biopsy. Liquid biopsy is a technique that involves collecting bodily fluids, such as blood, from patients and analyzing the tumor cells or substances derived from tumor cells present in the fluid. The advantage is that it can serve as an alternative when tumor tissue is not obtainable. Furthermore, it has the potential to detect disease progression and treatment resistance before clinical symptoms arise or before they can be identified through diagnostic means. Compared to traditional fine-needle aspiration cytology, liquid biopsy is less invasive, a short procedure, and can provide more comprehensive molecular information [41]. Circulating tumor DNA which encompasses genetic mutations and abnormal methylation status, the expression levels of circulating tumor RNA, gene expression of circulating tumor cells and epithelial cells, and the expression levels of exosome-derived RNA in the extracellular vesicles, are analyzed to extract molecular information from patients. These markers have been utilized as indicators for diagnosis, prognosis, and treatment response in major types of thyroid cancer such as DTC, ATC, and MTC, demonstrating their utility [41]. Although there are no reports specifically examining the correlation between peripheral blood data and local data in thyroid cancer. In Japan, liquid biopsy is currently approved and covered by insurance for non-small cell lung cancer, colorectal cancer, and solid tumors. Despite the challenges, we believe liquid biopsy can serve as a valuable resource to support clinical decision-making in patients with thyroid cancer by aiding in the definition of diagnosis, prognosis prediction, assessment of treatment response, and disease management.

5. Conclusions

We conducted IHC to examine the expression of PD-L1, CD8, and the presence of BRAFV600E mutation in thyroid cancer. The results showed that 39.4% of all patients exhibited positive expression of PD-L1. It was found that the presence of BRAFV600E mutation, positive expression of CD8, and decrease in T cell activity were associated with PD-L1 positivity. Although no clear associations were shown, there was a tendency for better prognosis when there was a higher infiltration of CD8+ T cells within the tumor, while it was not demonstrated that high expression of PD-L1 in tumor cells was an independent poor prognostic factor. However, comprehensive evaluation of PD-L1 expression, CD8 expression, BRAFV600E mutation, and the patient’s immune status suggested the potential of serving as predictive indicators for the prognosis. In other words, the immune status of the tumor microenvironment in thyroid cancer is an important factor that influences patient prognosis. The results showed that the immunological composition of the tumor microenvironment and inflammatory conditions are influencing the progression of thyroid cancer through the involvement of PD-L1. It was suggested that immune response suppression factors such as T cell dysfunction and exhaustion, decreased production of cytokines, the presence and activity of immunosuppressive cells (MDSCs), chronic inflammatory states, and tumor-associated inflammation contribute to immune response suppression. Further research is necessary to understand the mechanisms underlying PD-L1 expression.
By comprehensively evaluating factors such as PD-L1 expression, CD8 expression, BRAFV600E mutation, and the patient’s immune status, it may be possible to stratify patients who are likely to benefit from anti-PD-L1 antibody therapy and propose effective treatment combinations. For example, even among PD-L1-positive patients, there is a trend suggesting that prognosis may vary depending on whether CD8 is positive or negative, indicating differences in T cell activity. From this observation, it can be inferred that PD-L1-positive and CD8-negative patients may have impaired tumor cell attack by T cells due to upregulation of PD-L1. Therefore, in addition to inhibiting PD-L1 with anti-PD-L1 antibody therapy, considering the selection of therapies such as CAR-T cell therapy to activate T cells, 4-1BB agonist antibody, and OX40 agonist antibody may be worthwhile.
Additionally, preoperative CRP levels, which have been identified as prognostic factors, may serve as useful markers in the development of novel therapies such as targeted molecular agents. Continued investigation is warranted to evaluate their utility in future therapeutic advancements. Further research is needed to elucidate the prognostic and therapeutic value of PD-L1 expression in thyroid cancer.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cancers15133449/s1, Figure S1: Kaplan–Meier curves for PFS. Table S1. Results summary.

Author Contributions

Conceptualization, M.S., M.I. and S.S. (Shinichi Suzuki); methodology, M.S., M.I. and S.S. (Shinichi Suzuki); formal analysis, M.S.; investigation, M.S., M.I. and Y.Y.; resources, M.S., M.I. and S.S. (Shinichi Suzuki); data curation, M.S.; writing—original draft preparation, M.S. and M.I.; writing—review and editing, M.S., M.I., Y.M., S.S. (Satoshi Suzuki), H.M., K.N., I.N. and S.S. (Shinichi Suzuki); visualization, M.S., M.I. and S.S. (Shinichi Suzuki); supervision, M.I. and S.S. (Shinichi Suzuki); project administration, S.S. (Shinichi Suzuki); funding acquisition, S.S. (Shinichi Suzuki). All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of Fukushima Medical University (approval no. 29195).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The data presented in this study are available on request from the corresponding author.

Acknowledgments

We express our gratitude to all the participating patients. We also thank Masahiko Shibata (Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, Fukushima) for providing us with some of the data of blood samples.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Sugitani, I.; Miyauchi, A.; Sugino, K.; Okamoto, T.; Yoshida, A.; Suzuki, S. Prognostic Factors and Treatment Outcomes for Anaplastic Thyroid Carcinoma: ATC Research Consortium of Japan Cohort Study of 677 Patients. World J. Surg. 2012, 36, 1247–1254. [Google Scholar] [CrossRef]
  2. Ozmen, S.; Timur, O.; Calik, I.; Altinkaynak, K.; Simsek, E.; Gozcu, H.; Arslan, A.; Carlioglu, A. Neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) may be superior to C-reactive protein (CRP) for predicting the occurrence of differentiated thyroid cancer. Endocr. Regul. 2017, 51, 131–136. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Shimura, T.; Shibata, M.; Gonda, K.; Matsumoto, Y.; Nakano, K.; Iwadate, M.; Suzuki, S.; Suzuki, S. Prognostic impact of elevated preoperative C-reactive protein on patients with differentiated thyroid carcinoma. J. Surg. Res. 2018, 231, 338–345. [Google Scholar] [CrossRef] [PubMed]
  4. Mehnert, J.M.; Varga, A.; Brose, M.S.; Aggarwal, R.R.; Lin, C.C.; Prawira, A.; DeBraud, F.; Tamura, K.; Doi, T.; Piha-Paul, S.A.; et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer. BMC Cancer 2019, 19, 196. [Google Scholar] [CrossRef]
  5. Reck, M.; Rodriguez-Abreu, D.; Robinson, A.G.; Hui, R.; Csőszi, T.; Andrea Fülöp, A.; Maya Gottfried, M.; Peled, N.; Tafreshi, A.; Cuffe, S.; et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 2016, 375, 1823–1833. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Carbone, D.P.; Reck, M.; Paz-Ares, L.; Creelan, B.; Horn, L.; Steins, M.; Felip, E.; van den Heuvel, M.M.; Ciuleanu, T.E.; Badin, F.; et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N. Engl. J. Med. 2017, 376, 2415–2426. [Google Scholar] [CrossRef] [PubMed]
  7. Rizvi, N.A.; Hellmann, M.D.; Snyder, A.; Kvistborg, P.; Makarov, V.; Havel, J.J.; Lee, W.; Yuan, J.; Wong, P.; Ho, T.S.; et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015, 348, 124–128. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  8. Tumeh, P.C.; Harview, C.L.; Yearley, J.H.; Shintaku, I.P.; Taylor, E.J.; Robert, L.; Chmielowski, B.; Spasic, M.; Henry, G.; Ciobanu, V.; et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014, 515, 568–571. [Google Scholar] [CrossRef] [Green Version]
  9. Karasaki, T.; Nagayama, K.; Kuwano, H.; Nitadori, J.I.; Sato, M.; Anraku, M.; Hosoi, A.; Matsushita, H.; Morishita, Y.; Kashiwabara, K.; et al. An Immunogram for the Cancer- Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer. J. Thorac. Oncol. 2017, 12, 791–803. [Google Scholar] [CrossRef] [Green Version]
  10. Chen, D.S.; Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 2017, 541, 321–330. [Google Scholar] [CrossRef]
  11. Ohigashi, Y.; Sho, M.; Yamada, Y.; Tsurui, Y.; Hamada, K.; Ikeda, N.; Mizuno, T.; Yoriki, R.; Kashizuka, H.; Yane, K.; et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin. Cancer Res. 2005, 11, 2947–2953. [Google Scholar] [CrossRef] [Green Version]
  12. Konishi, J.; Yamazaki, K.; Azuma, M.; Kinoshita, I.; Dosaka-Akita, H.; Nishimura, M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin. Cancer Res. 2004, 10, 5094–5100. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Hino, R.; Kabashima, K.; Kato, Y.; Yagi, H.; Nakamura, M.; Honjo, T.; Okazaki, T.; Tokura, Y. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010, 116, 1757–1766. [Google Scholar] [CrossRef] [PubMed]
  14. Aghajani, M.; Graham, S.; McCafferty, C.; Shaheed, C.A.; Roberts, T.; DeSouza, P.; Yang, T.; Niles, N. Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 Expression in Patients with Non-Medullary Thyroid Cancer: A Systematic Review and Meta-Analysis. Thyroid 2018, 28, 349–361. [Google Scholar] [CrossRef] [PubMed]
  15. Chowdhury, S.; Veyhl, J.; Jessa, F.; Polyakova, O.; Alenzi, A.; MacMillan, C.; Ralhan, R.; Walfish, P.G. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants. Oncotarget 2016, 7, 32318–32328. [Google Scholar] [CrossRef] [PubMed]
  16. Cunha, L.L.; Marcello, M.A.; Vassallo, J.; Ward, L.S. Differentiated thyroid carcinomas and their B7H1 shield. Future Oncol. 2013, 9, 1417–1419. [Google Scholar] [CrossRef] [PubMed]
  17. Cunha, L.L.; Marcello, M.A.; Morari, E.C.; Nonogaki, S.; Conte, F.F.; Gerhard, R.; Soares, F.A.; Vassallo, J.; Ward, L.S. Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation. Endocr. Relat. Cancer 2013, 20, 103–110. [Google Scholar] [CrossRef] [Green Version]
  18. French, J.D.; Kotnis, G.R.; Said, S.; Raeburn, C.D.; McIntyre, R.C., Jr.; Klopper, J.P.; Haugen, B.R. Programmed death- 1+ T cells and regulatory T cells are enriched in tumor- involved lymph nodes and associated with aggressive features in papillary thyroid cancer. J. Clin. Endocrinol. Metab. 2012, 97, E934–E943. [Google Scholar] [CrossRef]
  19. Severson, J.J.; Serracino, H.S.; Mateescu, V.; Raeburn, C.D.; McIntyre, R.C., Jr.; Sams, S.B.; Haugen, B.R.; French, J.D. PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer. Cancer Immunol. Res. 2015, 3, 620–630. [Google Scholar] [CrossRef] [Green Version]
  20. Angell, T.E.; Lechner, M.G.; Jang, J.K.; Correa, A.J.; LoPresti, J.S.; Epstein, A.L. BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration. Thyroid 2014, 24, 1385–1393. [Google Scholar] [CrossRef] [Green Version]
  21. Brown, J.A.; Dorfman, D.M.; Ma, F.R.; Sullivan, E.L.; Munoz, O.; Wood, C.R.; Greenfield, E.A.; Freeman, G.J. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J. Immunol. 2003, 170, 1257–1266. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Colombo, C.; Giancola, N.; Fugazzola, L. Personalized treatment for differentiated thyroid cancer: Current data and new perspectives. Minerva Endocrinol. 2021, 46, 62–89. [Google Scholar] [CrossRef] [PubMed]
  23. Xing, M.; Alzahrani, A.S.; Carson, K.A.; Viola, D.; Elisei, R.; Bendlova, B.; Yip, L.; Mian, C.; Vianello, F.; Tuttle, R.M. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 2013, 309, 1493–1501. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Kondo, T.; Ezzat, S.; Ada, S.L. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat. Rev. Cancer 2006, 6, 292–306. [Google Scholar] [CrossRef]
  25. Ahn, S.; Kim, T.H.; Kim, S.W.; Ki, C.S.; Jang, H.W.; Kim, J.S.; Kim, J.H.; Choe, J.H.; Shin, J.H.; Hahn, S.Y. Comprehensive screening for PD-L1 expression in thyroid cancer. Endocr. Relat. Cancer 2017, 24, 97–106. [Google Scholar] [CrossRef] [Green Version]
  26. Xing, M. BRAF mutation in papillary thyroid cancer: Pathogenic role, molecular bases, and clinical implications. Endocr. Rev. 2007, 28, 742–762. [Google Scholar] [CrossRef]
  27. Suzuki, S.; Shibata, M.; Gonda, K.; Kanke, Y.; Ashizawa, M.; Ujiie, D.; Suzushino, S.; Nakano, K.; Fukushima, T.; Sakurai, K. Immunosuppression involving increased myeloid derived suppressor cell levels, systemic inflammation and hypoalbuminemia are present in patients with anaplastic thyroid cancer. Mol. Clin. Oncol. 2013, 1, 959–964. [Google Scholar] [CrossRef] [Green Version]
  28. Riella, L.V.; Paterson, A.M.; Sharpe, A.H.; Chandraker, A. Role of the PD-1 pathway in the immune response. Am. J. Transplant. 2012, 12, 2575–2587. [Google Scholar] [CrossRef] [Green Version]
  29. Sheffield, B.S.; Fulton, R.; Kalloger, S.E.; Milne, K.; Geller, G.; Jones, M.; Jacquemont, C.; Zachara, S.; Zhao, E.; Pleasance, E.; et al. Investigation of PD-L1 Biomarker testing methods for PD-1 axis inhibition in non-squamous non-small cell lung cancer. J. Histochem. Cytochem. 2016, 64, 587–600. [Google Scholar] [CrossRef] [Green Version]
  30. Chintakuntlawar, A.V.; Rumilla, K.M.; Smith, C.Y.; Jenkins, S.M.; Foote, R.L.; Kasperbauer, J.L.; Morris, J.C.; Ryder, M.; Alsidawi, S.; Hilger, C.; et al. Expression of PD-1 and PD-L1 in anaplastic thyroid cancer patients treated with multimodal therapy: Results from a retrospective study. J. Clin. Endocrinol. Metab. 2017, 102, 1943–1950. [Google Scholar] [CrossRef]
  31. Ogiya, R.; Niikura, N.; Kumaki, N.; Bianchini, G.; Kitano, S.; Iwamoto, T.; Hayashi, N.; Yokoyama, K.; Oshitanai, R.; Terao, M.; et al. Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients. Cancer Sci. 2016, 107, 1730–1735. [Google Scholar] [CrossRef]
  32. Tokoro, D.; Yane, Y.; Hida, J.; Okuno, K. Prognostic lmplications of Programmed Cell Death Ligand- 1 (PD-L1) Expression on Tumor- lnfiltrating lmmune Cells and CD8 + T Cells for Stage III Colorectal Cancer. Jpn. J. Cancer Chemother. 2018, 45, 1482–1485. Available online: http://ccpgan.com/ (accessed on 6 January 2020).
  33. Ashizawa, M.; Okayama, H.; Ishigame, T.; Aung Kyi Thar, M.i.n.; Saito, K.; Ujiie, D.; Murakami, M.; Kikuchi, T.; Nakayama, Y.; Noda, M.; et al. miRNA-148a-3p regulates immunosuppression in DNA mismatch repair-deficient colorectal cancer by targeting PD-L1. Mol. Cancer Res. 2019, 17, 1403–1413. [Google Scholar] [CrossRef] [Green Version]
  34. Ogino, S.; Galon, J.; Fuchs, C.S.; Dranoff, G. Cancer immunology- analysis of host and tumor factors for personalized medicine. Nat. Rev. Clin. Oncol. 2011, 8, 711–719. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Nikiforov, Y.E.; Seethala, R.R.; Tallini, G.; Baloch, Z.W.; Basolo, F.; Thompson, L.D.; Barletta, J.A.; Wenig, B.M.; Al Ghuzlan, A.; Kakudo, K.; et al. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. JAMA Oncol. 2016, 2, 1023–1029. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Fukushima, T.; Suzuki, S.; Mashiko, M.; Ohtake, T.; Endo, Y.; Takebayashi, Y.; Sekikawa, K.; Hagiwara, K.; Takenoshita, S. BRAF mutations in papillary carcinomas of the thyroid. Oncogene 2003, 22, 6455–6457. [Google Scholar] [CrossRef] [Green Version]
  37. Hirokawa, M.; Higuchi, M.; Suzuki, A.; Hayashi, T.; Kuma, A.; Miyauchi, A. Prevalence and diagnostic significance of noninvasive follicular thyroid neoplasm with papillary-like nuclear features among tumors previously diagnosed as follicular adenoma: A single-institutional study in Japan. Endocr. J. 2020, 67, 1071–1075. [Google Scholar] [CrossRef]
  38. Cunha, L.L.; Morari, E.C.; Guihen, A.C.; Razolli, D.; Gerhard, R.; Nonogaki, S.; Soares, F.A.; Vassallo, J.; Ward, L.S. Infiltration of a mixture of immune cells may be related to good prognosis in patients with differentiated thyroid carcinoma. Clin. Endocrinol. 2012, 77, 918–925. [Google Scholar] [CrossRef]
  39. Ieni, A.; Vita, R.; Pizzimenti, C.; Benvenga, S.; Tuccari, G. Intratumoral heterogeneity in differentiated thyroid tumors: An intriguing reappraisal in the era of personalized medicine. J. Pers. Med. 2021, 11, 333. [Google Scholar] [CrossRef]
  40. Nicolson, N.G.; Paulsson, J.O.; Juhlin, C.C.; Carling, T.; Korah, R. Transcription factor profiling identifies spatially heterogenous mediators of follicular thyroid cancer invasion. Endocr. Pathol. 2020, 31, 367–376. [Google Scholar] [CrossRef]
  41. Pogliaghi, G. Liquid biopsy in thyroid cancer: From circulating biomarkers to a new prospective of tumor monitoring and therapy. Minerva Endocrinol. 2021, 46, 45–61. [Google Scholar] [CrossRef] [PubMed]
Cancers 15 03449 g001 550
Figure 1. PD-L1 IHC and image analysis. PD-L1 IHC was analyzed using image analysis software Patholoscope at 400 magnification. (a–c) PD-L1 expression in papillary thyroid cancer by immunohistochemistry. (d–f) In the immunostaining image format, cells stained red indicate strong expression of PD-L1, and blue indicates weak expression of PD-L1. Both red and blue cells were counted automatically. (a,d) The percentage of PD-L1-positive staining was 0%. (b,e) The percentage of PD-L1-positive staining was 0.79%. (c,f) The percentage of PD-L1-positive staining was 16.5%. All photomicrographs were magnified ×200.
Figure 1. PD-L1 IHC and image analysis. PD-L1 IHC was analyzed using image analysis software Patholoscope at 400 magnification. (a–c) PD-L1 expression in papillary thyroid cancer by immunohistochemistry. (d–f) In the immunostaining image format, cells stained red indicate strong expression of PD-L1, and blue indicates weak expression of PD-L1. Both red and blue cells were counted automatically. (a,d) The percentage of PD-L1-positive staining was 0%. (b,e) The percentage of PD-L1-positive staining was 0.79%. (c,f) The percentage of PD-L1-positive staining was 16.5%. All photomicrographs were magnified ×200.
Cancers 15 03449 g001
Cancers 15 03449 g002 550
Figure 2. CD8+ IHC and image analysis. CD8+ IHC was analyzed using the software Patholoscope, v1.0 (MITANI Co., Tokyo, Japan) a computerized image analysis system. (a–c) The picture of the immunohistochemistry staining of CD8+ T-cell is shown. (d–f) From the immunostaining image format, the software extracted positive cells (small orange circles) and negative cells (small purple circles), and counted them automatically. As the orange circles were not clear when we pasted the images, the author re-emphasized the orange markings. (a,d) The tumor sections from the same patient as in Figure 1 (a,d) were used. (b,e) The tumor sections from the same patient as in Figure 1 (b,e) were used. (c,f) The tumor sections from the same patient as in Figure 1 (c,f) were used. All photomicrographs were magnified ×200.
Figure 2. CD8+ IHC and image analysis. CD8+ IHC was analyzed using the software Patholoscope, v1.0 (MITANI Co., Tokyo, Japan) a computerized image analysis system. (a–c) The picture of the immunohistochemistry staining of CD8+ T-cell is shown. (d–f) From the immunostaining image format, the software extracted positive cells (small orange circles) and negative cells (small purple circles), and counted them automatically. As the orange circles were not clear when we pasted the images, the author re-emphasized the orange markings. (a,d) The tumor sections from the same patient as in Figure 1 (a,d) were used. (b,e) The tumor sections from the same patient as in Figure 1 (b,e) were used. (c,f) The tumor sections from the same patient as in Figure 1 (c,f) were used. All photomicrographs were magnified ×200.
Cancers 15 03449 g002
Cancers 15 03449 g003 550
Figure 3. Kaplan–Meier curves for PFS; (a) with negative or positive PD-L1 expression, (b) with BRAFV600E mutation or wild type, and (c) with negative or positive CD8+ expression. *: statistically significant.
Figure 3. Kaplan–Meier curves for PFS; (a) with negative or positive PD-L1 expression, (b) with BRAFV600E mutation or wild type, and (c) with negative or positive CD8+ expression. *: statistically significant.
Cancers 15 03449 g003
Table
Table 1. Correlations between PD-L1 expression and clinicopathological factors in thyroid cancer.
Table 1. Correlations between PD-L1 expression and clinicopathological factors in thyroid cancer.
CharacteristicsPD-L1 Expression
Negative (n = 20)		PD-L1 Expression
Positive (n = 13)		p-Value
Age53.9 ± 12.563.3 ± 14.50.071
Sex
Male820.132
Female1211
Thyroid cancer
PTC14100.315
ATC23
FTC20
MTC20
Tumor size25.8 ± 20.034.2 ± 25.50.276
Ex
Ex0960.449
EX183
EX234
pT
T1a340.794
T1b62
T221
T352
T4a11
T4b33
pN
N0670.201
N1a30
N1b116
M
M015110.419
M152
STAGE
I550.678
II10
III31
IV117
CRP (mg/dL)0.19 ± 0.281.5 ± 5.00.429
WBC (103/μL)5.8 ± 3.47.4 ± 7.50.568
NLR (%)6.9 ± 19.64.1 ± 4.10.2
LMR (%)5.4 ± 3.43.9 ± 2.10.13
SI694.8 ± 524.0346.6 ± 219.00.046 *
IL-10 (µg/mL)2134.9 ± 2661.82488.3 ± 3113.30.815
IL-17 (µg/mL)834.2 ± 1785.7480.8 ± 606.70.741
IL-12 (µg/mL)116.6 ± 93.891.4 ± 112.30.256
IFN-γ (µg/mL)3943.1 ± 2695.93058 ± 2321.70.459
VEGF (pg/mL)369.1 ± 380.12246.2 ± 4617.40.805
MDSC (%PBMC)1.7 ± 1.71.5 ± 1.30.626
BRAFV600E
Wild type810.047 *
Mutation1212
CD8
Negative1420.003 *
Positive611
Data are shown as mean ± s.d. or number of cases (percentage). *: statistically significant. PTC, papillary thyroid cancer; ATC, anaplastic thyroid cancer; FTC, follicular thyroid cancer; MTC, Medullary thyroid cancer; CRP, c-reactive protein; WBC, white blood cell; NLR, neutrophil–lymphocyte ratio; LMR, lymphocyte–monocyte ratio; SI, Stimulation Index is one of the markers of inflammation; IL, interleukin; VEGF, vascular endothelial growth factor; MDSC, myeloid-derived suppressor cells; BRAF, v-raf murine sarcoma viral oncogene homolog B1.
Table
Table 2. Univariate analysis of clinicopathological factors associated with PFS.
Table 2. Univariate analysis of clinicopathological factors associated with PFS.
CharacteristicsHR95%CI
Lower		95%CI
Upper		p-Value
Age
<55 vs. ≥55 years2.370.757.490.14
Sex
Male vs. Female0.570.21.010.290
Tumor size
<20 vs. ≥20 (mm)7.791.7434.780.007 *
Thyroid cancer
DTC vs. ATC4.971.5316.180.008 *
Ex
Ex01///
Ex13.60.8914.470.072
Ex29.32.2837.90.002 *
pT
T11///
T21.280.1312.380.829
T33.80.8417.220.084
T48.122.0731.860.003 *
pN
N0 vs. N13.450.9712.250.056
M
M0 vs. M15.731.9816.580.001 *
Stage
I–II vs. III–IV3.850.8717.080.076
CRP
<0.15 vs. ≥0.15 (mg/dL)5.081.8014.320.002 *
WBC
<8.6 vs. ≥8.6 (103/μL)30.932.81340.820.005 *
NLR
Low vs. High2.08 0.69 6.230.191
LMR
Low vs. High0.58 0.20 1.690.321
SI
Low vs. High0.500.151.700.266
VEGF
Low vs. High9.021.2664.760.029 *
IL10
Low vs. High0.310.071.490.145
IL17
Low vs. High0.380.052.970.353
IL12
Low vs. High0.430.092.020.283
IFNγ
Low vs. High3.160.8811.290.077
MDSC
Low vs. High1.480.504.350.476
CD8
Negative vs. Positive0.430.151.260.122
BRAFV600E
Wild type vs. Mutation0.270.100.760.013 *
PD-L1
Negative vs. Positive1.040.372.910.947
HR: Hazard Ratio. *: statistically significant. DTC, differentiated thyroid cancer; ATC, anaplastic thyroid cancer; CRP, c-reactive protein; WBC, white blood cell; NLR, neutrophil–lymphocyte ratio; LMR, lymphocyte–monocyte ratio; SI, Stimulation Index is one of the markers of inflammation; VEGF, vascular endothelial growth factor; IL, interleukin; MDSC, myeloid-derived suppressor cells; BRAF, v-raf murine sarcoma viral oncogene homolog B1.
Table
Table 3. Multivariate analysis of clinicopathological factors associated with PFS.
Table 3. Multivariate analysis of clinicopathological factors associated with PFS.
CharacteristicsHR95%CI
Lower		95%CI
Upper		p-Value
CRP
<0.15 vs. ≥0.15 (mg/dL)14.341.14179.750.039 *
WBC
<8.6 vs. ≥8.6 (103/μL)9.560.63144.460.103
VEGF
Low vs. high3.830.3147.410.295
BRAFV600E
Wild type vs. Mutation0.040.000.620.022 *
PD-L1
Negative vs. positive2.090.3213.870.445
HR: Hazard Ratio. *: statistically significant. 95%CI, 95% Confidence interval; CRP, c-reactive protein; WBC, white blood cell; VEGF, vascular endothelial growth factor; BRAF, v-raf murine sarcoma viral oncogene homolog B1.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Sekino, M.; Iwadate, M.; Yamaya, Y.; Matsumoto, Y.; Suzuki, S.; Mizunuma, H.; Nakano, K.; Nakamura, I.; Suzuki, S. Analysis of Expression of Programmed Cell Death Ligand 1 (PD-L1) and BRAFV600E Mutation in Thyroid Cancer. Cancers 2023, 15, 3449. https://doi.org/10.3390/cancers15133449

AMA Style

Sekino M, Iwadate M, Yamaya Y, Matsumoto Y, Suzuki S, Mizunuma H, Nakano K, Nakamura I, Suzuki S. Analysis of Expression of Programmed Cell Death Ligand 1 (PD-L1) and BRAFV600E Mutation in Thyroid Cancer. Cancers. 2023; 15(13):3449. https://doi.org/10.3390/cancers15133449

Chicago/Turabian Style

Sekino, Mizuki, Manabu Iwadate, Yukie Yamaya, Yoshiko Matsumoto, Satoshi Suzuki, Hiroshi Mizunuma, Keiichi Nakano, Izumi Nakamura, and Shinichi Suzuki. 2023. "Analysis of Expression of Programmed Cell Death Ligand 1 (PD-L1) and BRAFV600E Mutation in Thyroid Cancer" Cancers 15, no. 13: 3449. https://doi.org/10.3390/cancers15133449

APA Style

Sekino, M., Iwadate, M., Yamaya, Y., Matsumoto, Y., Suzuki, S., Mizunuma, H., Nakano, K., Nakamura, I., & Suzuki, S. (2023). Analysis of Expression of Programmed Cell Death Ligand 1 (PD-L1) and BRAFV600E Mutation in Thyroid Cancer. Cancers, 15(13), 3449. https://doi.org/10.3390/cancers15133449

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop